Elevated Striatal Glutamate + Glutamine in Recreational Cannabis Users During Abstinence

Overview

Journal J Psychiatr Res

Specialty Psychiatry

Date 2022 Jan 9

PMID 34999370

Citations 2

Authors

Chun S Zuo

Katherine A Davis

Madeline K Kuppe

M Kathryn Dahlgren

Staci Gruber

Garrett M Fitzmaurice

Scott E Lukas

Affiliations

Soon will be listed here.

Abstract

Cannabis withdrawal symptoms contribute to relapse, but the underlying mechanism remains unclear. We hypothesize that cannabis withdrawal may be associated with a reset of regional γ-amino butyric acid (GABA) and glutamate concentrations secondary to changes in the endocannabinoid system during abstinence and conducted a study on this issue. We used magnetic resonance spectroscopy (MRS) to detect the associated changes of these neurochemicals in twenty-six frequent, recreational cannabis users and eleven age-matched non-using controls. Twenty users (8F/12M) and ten control (5F/5M) participants completed a verified 21-day abstinence period. Striatal GABA and glutamine concentrations were measured at baseline and on abstinence days 7 and 21 in conjunction with measures of cannabis withdrawal symptoms and mood state. Cannabis users reported increased self-reported ratings of cannabis-withdrawal-symptoms on abstinence day 7 relative to controls. Striatal glutamate + glutamine (Glx) group concentrations were elevated in cannabis users at baseline and abstinence days 7 and 21 (F = 7.16, p = 0.012), and changes in GABA concentration and withdrawal symptoms between baseline and abstinence day 7 were positively correlated (r = 0.550, p = 0.010). In addition, baseline striatal GABA concentrations were negatively correlated with withdrawal symptoms on abstinence day 7 (r = -0.680, p = 0.003). Our data demonstrate that striatal Glx was elevated in cannabis users and baseline striatal GABA correlated with withdrawal during the abstinence. In addition, striatal GABA may temporally correlate with self-reported withdrawal symptoms during the initial days of abrupt cannabis abstinence. These findings provide preliminary evidence that striatal GABA and Glx are associated with the severity of cannabis withdrawal.

Citing Articles

Chronic cannabis use alters dACC-striatal glutamatergic balance.

Zuo C, Lukas S Pharmacol Biochem Behav. 2023; 225:173544.

PMID: 37004979 PMC: 10192043. DOI: 10.1016/j.pbb.2023.173544.

Lower dACC glutamate in cannabis users during early phase abstinence.

Zuo C, Davis K, Lukas S Neuropsychopharmacology. 2022; 47(11):1969-1975.

PMID: 35484401 PMC: 9485248. DOI: 10.1038/s41386-022-01321-5.

References

Compton W, Han B, Jones C, Blanco C, Hughes A . Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. Lancet Psychiatry. 2016; 3(10):954-964. DOI: 10.1016/S2215-0366(16)30208-5. View

Lisdahl K, Gilbart E, Wright N, Shollenbarger S . Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013; 4:53. PMC: 3696957. DOI: 10.3389/fpsyt.2013.00053. View

Provencher S . Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001; 14(4):260-4. DOI: 10.1002/nbm.698. View

Gleich T, Deserno L, Lorenz R, Boehme R, Pankow A, Buchert R . Prefrontal and Striatal Glutamate Differently Relate to Striatal Dopamine: Potential Regulatory Mechanisms of Striatal Presynaptic Dopamine Function?. J Neurosci. 2015; 35(26):9615-21. PMC: 6605144. DOI: 10.1523/JNEUROSCI.0329-15.2015. View

Hirvonen J, Goodwin R, Li C, Terry G, Zoghbi S, Morse C . Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2011; 17(6):642-9. PMC: 3223558. DOI: 10.1038/mp.2011.82. View

Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62. PMC: 495331. DOI: 10.1136/jnnp.23.1.56. View

Chang L, Cloak C, Yakupov R, Ernst T . Combined and independent effects of chronic marijuana use and HIV on brain metabolites. J Neuroimmune Pharmacol. 2007; 1(1):65-76. PMC: 4899040. DOI: 10.1007/s11481-005-9005-z. View

Budney A, Moore B, Vandrey R, Hughes J . The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003; 112(3):393-402. DOI: 10.1037/0021-843x.112.3.393. View

DSouza D, Cortes-Briones J, Ranganathan M, Thurnauer H, Creatura G, Surti T . Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018; 1(1):60-67. DOI: 10.1016/j.bpsc.2015.09.008. View

10.

Huestis M, Mitchell J, Cone E . Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol. 1996; 20(6):441-52. DOI: 10.1093/jat/20.6.441. View

11.

Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa G . Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002; 948(1-2):155-8. DOI: 10.1016/s0006-8993(02)03055-x. View

12.

Hurd R, Sailasuta N, Srinivasan R, Vigneron D, Pelletier D, Nelson S . Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med. 2004; 51(3):435-40. DOI: 10.1002/mrm.20007. View

13.

Kouri E, Pope Jr H, Lukas S . Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology (Berl). 1999; 143(3):302-8. DOI: 10.1007/s002130050951. View

14.

Katona I, Freund T . Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008; 14(9):923-30. DOI: 10.1038/nm.f.1869. View

15.

Prescot A, Locatelli A, Renshaw P, Yurgelun-Todd D . Neurochemical alterations in adolescent chronic marijuana smokers: a proton MRS study. Neuroimage. 2011; 57(1):69-75. PMC: 3101285. DOI: 10.1016/j.neuroimage.2011.02.044. View

16.

Jensen J, Frederick B, Renshaw P . Grey and white matter GABA level differences in the human brain using two-dimensional, J-resolved spectroscopic imaging. NMR Biomed. 2005; 18(8):570-6. DOI: 10.1002/nbm.994. View

17.

Kadden R, Litt M, Kabela-Cormier E, Petry N . Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav. 2006; 32(6):1220-36. PMC: 1903379. DOI: 10.1016/j.addbeh.2006.08.009. View

18.

Allsop D, Copeland J, Norberg M, Fu S, Molnar A, Lewis J . Quantifying the clinical significance of cannabis withdrawal. PLoS One. 2012; 7(9):e44864. PMC: 3458862. DOI: 10.1371/journal.pone.0044864. View

19.

Kouri E, Pope Jr H . Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol. 2000; 8(4):483-92. DOI: 10.1037//1064-1297.8.4.483. View

20.

Mullins P, Chen H, Xu J, Caprihan A, Gasparovic C . Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn Reson Med. 2008; 60(4):964-9. DOI: 10.1002/mrm.21696. View